Comparison of Long-term Efficacy of Domestic TAVR vs. Corevalve
Journal: Journal of Clinical Medicine Research DOI: 10.32629/jcmr.v5i2.2325
Abstract
Aim: To assess the long-term effects of domestic valves and compare them with similar products to demonstrate non-inferiority and provide guidance for valve selection in severe aortic stenosis patients. Methods: The study comprised two parts: evaluating the long-term effects of domestic valves through follow-up data, and conducting a meta-analysis to assess the long-term efficacy of Corevalve. Results: Both valves showed high cumulative all-cause mortality and cardiac mortality rates at 5 years post-surgery, with statistically significant differences. There were also significant differences in the cumulative incidence rates of new pacemaker implantation and cardiac rehospitalization. Stroke and myocardial infarction event rates within 5 years were both below 10%, with no statistically significant differences. Conclusion: Domestic valves demonstrated favorable long-term effects, performing comparably or even superior to Corevalve in certain aspects.
Keywords
aortic stenosis; transcatheter aortic valve replacement; TAVR
Full Text
PDF - Viewed/Downloaded: 3 TimesReferences
[1] Xi Wang, Yijian Li, Yuanweixiang Ou, et al. Comparison of Clinical Application Between Venus A-Valve and Imported Valves in Transcatheter Aortic Valve Replacement[J]. West China Medical Journal. 2019, 34(04): 379-84.
[2] Runlin Gao, Shu Zhang, Zengwu Wang, et al. Development of Cardiovascular Medicine in China Since the Founding of the People's Republic of China[J]. Chinese Circulation Journal. 2019, 34(09): 833-43.
[3] BARBANTI M, PETRONIO A S, ETTORI F, et al. 5-Year Outcomes after Transcatheter Aortic Valve Implantation with CoreValve Prosthesis [J]. JACC: Cardiovascular Interventions, 2015, 8(8): 1084-91.
[4] AVANZAS P, PASCUAL I, MUñOZ-GARCíA A J, et al. Long-term Follow-up of Patients With Severe Aortic Stenosis Treated With a Self-expanding Prosthesis [J]. Revista espanola de cardiologia (English ed), 2017, 70(4): 247-53.
[5] GERCKENS U, TAMBURINO C, BLEIZIFFER S, et al. Final 5-year clinical and echocardiographic results for treatment of severe aortic stenosis with a self-expanding bioprosthesis from the ADVANCE Study [J]. European heart journal, 2017, 38(36): 2729-38.
[6] GLEASON T G, REARDON M J, POPMA J J, et al. 5-Year Outcomes of Self-Expanding Transcatheter Versus Surgical Aortic Valve Replacement in High-Risk Patients [J]. Journal of the American College of Cardiology, 2018, 72(22): 2687-96.
[7] HOLY E W, KEBERNIK J, ABDELGHANI M, et al. Long-term durability and haemodynamic performance of a self-expanding transcatheter heart valve beyond five years after implantation: a prospective observational study applying the standardised definitions of structural deterioration and valve failure [J]. EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 2018, 14(4): e390-e6.
[8] VOLLENBROICH R, WENAWESER P, MACHT A, et al. Long-term outcomes with balloon-expandable and self-expandable prostheses in patients undergoing transfemoral transcatheter aortic valve implantation for severe aortic stenosis [J]. Kardiovaskulare Medizin, 2019, 22(3).
[9] ABDEL-WAHAB M, LANDT M, NEUMANN F J, et al. 5-Year Outcomes After TAVR With Balloon-Expandable Versus Self-Expanding Valves: Results From the CHOICE Randomized Clinical Trial [J]. JACC: Cardiovascular Interventions, 2020, 13(9): 1071-82.
[10] ARNOLD S V, PETROSSIAN G, REARDON M J, et al. Five-Year Clinical and Quality of Life Outcomes From the CoreValve US Pivotal Extreme Risk Trial [J]. Circulation: Cardiovascular Interventions, 2021, 14(6): E010258.
[2] Runlin Gao, Shu Zhang, Zengwu Wang, et al. Development of Cardiovascular Medicine in China Since the Founding of the People's Republic of China[J]. Chinese Circulation Journal. 2019, 34(09): 833-43.
[3] BARBANTI M, PETRONIO A S, ETTORI F, et al. 5-Year Outcomes after Transcatheter Aortic Valve Implantation with CoreValve Prosthesis [J]. JACC: Cardiovascular Interventions, 2015, 8(8): 1084-91.
[4] AVANZAS P, PASCUAL I, MUñOZ-GARCíA A J, et al. Long-term Follow-up of Patients With Severe Aortic Stenosis Treated With a Self-expanding Prosthesis [J]. Revista espanola de cardiologia (English ed), 2017, 70(4): 247-53.
[5] GERCKENS U, TAMBURINO C, BLEIZIFFER S, et al. Final 5-year clinical and echocardiographic results for treatment of severe aortic stenosis with a self-expanding bioprosthesis from the ADVANCE Study [J]. European heart journal, 2017, 38(36): 2729-38.
[6] GLEASON T G, REARDON M J, POPMA J J, et al. 5-Year Outcomes of Self-Expanding Transcatheter Versus Surgical Aortic Valve Replacement in High-Risk Patients [J]. Journal of the American College of Cardiology, 2018, 72(22): 2687-96.
[7] HOLY E W, KEBERNIK J, ABDELGHANI M, et al. Long-term durability and haemodynamic performance of a self-expanding transcatheter heart valve beyond five years after implantation: a prospective observational study applying the standardised definitions of structural deterioration and valve failure [J]. EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 2018, 14(4): e390-e6.
[8] VOLLENBROICH R, WENAWESER P, MACHT A, et al. Long-term outcomes with balloon-expandable and self-expandable prostheses in patients undergoing transfemoral transcatheter aortic valve implantation for severe aortic stenosis [J]. Kardiovaskulare Medizin, 2019, 22(3).
[9] ABDEL-WAHAB M, LANDT M, NEUMANN F J, et al. 5-Year Outcomes After TAVR With Balloon-Expandable Versus Self-Expanding Valves: Results From the CHOICE Randomized Clinical Trial [J]. JACC: Cardiovascular Interventions, 2020, 13(9): 1071-82.
[10] ARNOLD S V, PETROSSIAN G, REARDON M J, et al. Five-Year Clinical and Quality of Life Outcomes From the CoreValve US Pivotal Extreme Risk Trial [J]. Circulation: Cardiovascular Interventions, 2021, 14(6): E010258.
Copyright © 2024 Menglun Zhou, Hengjin Dong
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License